QUINTESSENTIAL-2
A Phase 3 Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-Exposed Multiple Myeloma
What will happen during the trial?
This trial is seeking approximately 440 participants. Participants will be randomized into one of two groups (or arms). Participants in Arm A will receive treatment with a GPRC5D T-Cell therapy, BMS-986393. Participants in Arm B will receive one of two standard of care regimens, Daratumumab + Pomalidomide + Dexamethasone or Carfilzomib + Dexamethasone. This trial is open-label, which means that both researchers and participants will know which arms they are placed in, and which therapies they will be receiving.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 440 patients (estimated)
- Tags
- CAR T Cell, GPRC5D, Quadruplet Therapy, Randomization
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 1996
- NCT Identifier
- NCT06615479
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.